US Patent Issued to Suzhou Alphamab on March 24 for "Monoclonal antibody which targets TFPI" (Chinese Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,583,940, issued on March 24, was assigned to Suzhou Alphamab Co. Ltd. (Jiangsu, China).

"Monoclonal antibody which targets TFPI" was invented by Ting Xu (Jiangsu, China), Xiaoxiao Wang (Jiangsu, China), Ying Fan (jiangsu, China), Yanrong Dong (Jiangsu, China), Liping Chen (Jiangsu, China) and Jianyun Ji (Jiangsu, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is a monoclonal antibody or an antigen binding fragment thereof which targets tissue factor pathway inhibitor (TFPI), and a medical use thereof."

The patent was filed on Aug. 28, 2020, under Application No. 17/639,139.

*For further information, including images, charts and tables...